BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Novartis  Europharm  Ltd.  submitted  on  25  July  2006  an  application  for  Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Galvus,  through  the  centralised 
procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004. The 
eligibility to the centralised procedure was agreed upon by the EMEA/CHMP on 30 January 2006 . 
The  legal  basis  for  this  application  refers  to  Article  8.3  of  Directive  2001/83/EC,  as  amended  - 
complete and independent application. 
The application submitted is a complete dossier: composed of administrative information, complete 
quality data, non-clinical and clinical data based on applicants’ own tests and studies and/or 
bibliographic literature substituting/supporting certain tests or studies. 
Scientific Advice 
The applicant received Scientific Advice from the CHMP on 21 November 2003, 24 June 2004 and on 
22 October 2004. The Scientific Advice pertained to clinical aspects of the dossier.  
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: 
Rapporteur: Bengt Ljungberg  Co-Rapporteur: Pierre Demolis 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 25 July 2006. 
The procedure started on 16 August 2006.  
The Rapporteur's first Assessment Report was circulated to all CHMP members on 27 October 
2006. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 31 
October 2006.  
During  the  meeting  on  14  December  2006  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 15 December 2006. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  14 
March 2007. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 27 April 2007. 
During the CHMP meeting on 24 May 2007 the CHMP agreed on a list of outstanding issues to 
be addressed in writing and in an oral explanation by the applicant. 
During the meeting on 16-19 July 2007 the CHMP, in the light of the overall data submitted and 
the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing  Authorisation  to  Galvus  on  19  July  2007.  The  applicant  provided  the  letter  of 
undertaking on the follow-up measures to be fulfilled post-authorisation on 16 July 2007. 
1/1 
© EMEA 2007 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
